| 1 |
33669837 | Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents. | 2021 Feb 19 |
3 |
| 2 |
32784599 | DNA Methylation as a Therapeutic Target for Bladder Cancer. | 2020 Aug 7 |
2 |
| 3 |
29795051 | Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. | 2018 May 24 |
1 |
| 4 |
26960675 | Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes. | 2016 |
1 |
| 5 |
27003313 | Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs. | 2016 Jun |
1 |
| 6 |
27036028 | Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine. | 2016 May 10 |
1 |
| 7 |
23940695 | Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies. | 2013 |
1 |
| 8 |
21554144 | Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study. | 2011 Jun |
3 |
| 9 |
28210112 | Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines. | 2010 |
1 |
| 10 |
18931345 | Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. | 2009 Jan 15 |
2 |
| 11 |
16273408 | Clinical experience with decitabine in North American patients with myelodysplastic syndrome. | 2005 Dec |
2 |